In January, the Indian Pharmaceutical Market (IPM) experienced a robust growth rate of 9.5%, driven by significant increases across all major therapy segments, as reported by Pharmarack, a market research firm. Key areas such as cardiac treatments, anti-infectives, and gastrointestinal medicines exhibited particularly strong volume expansions during the month.
IPM witnessed a total value growth of approximately ₹16,234 crore along with a 2% rise in unit sales in January. Notably, respiratory, pain relief/analgesics, urology, antineoplastics, and stomatologicals demonstrated higher unit growth rates. Leading the sales charts were popular medications like Augmentin, an antibiotic, and Glycomet GP, an anti-diabetes drug.
As reported by ETPhama.com, across the country’s four zones, the western region stood out with the highest unit growth of 5.5% in January. Among states, Tamil Nadu in the south, Uttar Pradesh in the west, and Uttarakhand in the north made the most substantial contributions to the market’s growth. Conversely, Telangana was the sole state to experience a decline, with a -5% dip in January.
